Retinopathy Of Prematurity - Pipeline Review, H2 2016

Retinopathy Of Prematurity - Pipeline Review, H2 2016


  • Products Id :- GMDHC8462IDB
  • |
  • Pages: 36
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Retinopathy Of Prematurity - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Retinopathy Of Prematurity - Pipeline Review, H2 2016', provides an overview of the Retinopathy Of Prematurity pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Retinopathy Of Prematurity, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Retinopathy Of Prematurity and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Retinopathy Of Prematurity

- The report reviews pipeline therapeutics for Retinopathy Of Prematurity by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Retinopathy Of Prematurity therapeutics and enlists all their major and minor projects

- The report assesses Retinopathy Of Prematurity therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Retinopathy Of Prematurity

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Retinopathy Of Prematurity

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Retinopathy Of Prematurity pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Retinopathy Of Prematurity Overview 6

Therapeutics Development 7

Pipeline Products for Retinopathy Of Prematurity - Overview 7

Retinopathy Of Prematurity - Therapeutics under Development by Companies 8

Retinopathy Of Prematurity - Pipeline Products Glance 9

Late Stage Products 9

Early Stage Products 10

Retinopathy Of Prematurity - Products under Development by Companies 11

Retinopathy Of Prematurity - Companies Involved in Therapeutics Development 12

Biomar Microbial Technologies 12

F. Hoffmann-La Roche Ltd. 13

Retinopathy Of Prematurity - Therapeutics Assessment 14

Assessment by Monotherapy Products 14

Assessment by Target 15

Assessment by Mechanism of Action 17

Assessment by Route of Administration 19

Assessment by Molecule Type 21

Drug Profiles 23

AP-202 - Drug Profile 23

Product Description 23

Mechanism Of Action 23

R&D Progress 23

IB-09A0133 - Drug Profile 24

Product Description 24

Mechanism Of Action 24

R&D Progress 24

R-200 - Drug Profile 25

Product Description 25

Mechanism Of Action 25

R&D Progress 25

ranibizumab - Drug Profile 26

Product Description 26

Mechanism Of Action 26

R&D Progress 26

Recombinant Protein for Cancer and Diabetic Retinopathy - Drug Profile 32

Product Description 32

Mechanism Of Action 32

R&D Progress 32

Retinopathy Of Prematurity - Dormant Projects 33

Retinopathy Of Prematurity - Discontinued Products 34

Appendix 35

Methodology 35

Coverage 35

Secondary Research 35

Primary Research 35

Expert Panel Validation 35

Contact Us 35

Disclaimer 36

List of Figures

Number of Products under Development for Retinopathy Of Prematurity, H2 2016 7

Number of Products under Development by Companies, H2 2016 8

Comparative Analysis by Early Stage Products, H2 2016 10

Assessment by Monotherapy Products, H2 2016 14

Number of Products by Targets, H2 2016 15

Number of Products by Stage and Targets, H2 2016 15

Number of Products by Mechanism of Actions, H2 2016 17

Number of Products by Stage and Mechanism of Actions, H2 2016 17

Number of Products by Routes of Administration, H2 2016 19

Number of Products by Stage and Routes of Administration, H2 2016 19

Number of Products by Molecule Types, H2 2016 21

Number of Products by Stage and Molecule Types, H2 2016 21

List of Tables

Number of Products under Development for Retinopathy Of Prematurity, H2 2016 7

Number of Products under Development by Companies, H2 2016 8

Comparative Analysis by Late Stage Development, H2 2016 9

Comparative Analysis by Early Stage Development, H2 2016 10

Products under Development by Companies, H2 2016 11

Retinopathy Of Prematurity - Pipeline by Biomar Microbial Technologies, H2 2016 12

Retinopathy Of Prematurity - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 13

Assessment by Monotherapy Products, H2 2016 14

Number of Products by Stage and Target, H2 2016 16

Number of Products by Stage and Mechanism of Action, H2 2016 18

Number of Products by Stage and Route of Administration, H2 2016 20

Number of Products by Stage and Molecule Type, H2 2016 22

Retinopathy Of Prematurity - Dormant Projects, H2 2016 33

Retinopathy Of Prematurity - Discontinued Products, H2 2016 34

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Biomar Microbial Technologies

F. Hoffmann-La Roche Ltd.

Retinopathy Of Prematurity Therapeutic Products under Development, Key Players in Retinopathy Of Prematurity Therapeutics, Retinopathy Of Prematurity Pipeline Overview, Retinopathy Of Prematurity Pipeline, Retinopathy Of Prematurity Pipeline Assessment

select a license

Single User License
USD 2000 INR 128720
Site License
USD 4000 INR 257440
Corporate User License
USD 6000 INR 386160

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com